TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients 英文论文文献.docVIP

下载本文档

5
0
约 7页
2017-05-08 发布于上海
举报

TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients 英文论文文献.doc

TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients 英文论文文献

K?rneretal.BMCCancer2012,12:85 /1471-2407/12/85 RESEARCH ARTICLE OpenAccess TRAILreceptorI(DR4)polymorphismsC626Gand A683Careassociatedwithanincreasedriskfor hepatocellularcarcinoma(HCC)inHCV-infected patients ChristianK?rner1,KatarinaRiesner1,BenjaminKr?mer1,MarianneEisenhardt1,AndreasGl?ssner1,FranziskaWolter1, ThomasBerg2,TobiasMüller3,TilmanSauerbruch1,JacobNattermann1,UlrichSpengler1and HansDieterNischalke1* Abstract Background:TumoursurveillanceviainductionofTRAIL-mediatedapoptosisisakeymechanism,howthe immunesystempreventsmalignancy.TodetermineifgenevariantsintheTRAILreceptorI(DR4)gene

您可能关注的文档

文档评论（0）

1亿VIP精品文档

更多 >

TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients 英文论文文献.docVIP